137 related articles for article (PubMed ID: 35166123)
1. Long-Term Disease Prevention with a Gene Therapy Targeting Oligodendrocytes in a Mouse Model of Adrenomyeloneuropathy.
Özgür-Günes Y; Chedik M; Le Stunff C; Fovet CM; Bougnères P
Hum Gene Ther; 2022 Sep; 33(17-18):936-949. PubMed ID: 35166123
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.
Gong Y; Berenson A; Laheji F; Gao G; Wang D; Ng C; Volak A; Kok R; Kreouzis V; Dijkstra IM; Kemp S; Maguire CA; Eichler F
Hum Gene Ther; 2019 May; 30(5):544-555. PubMed ID: 30358470
[TBL] [Abstract][Full Text] [Related]
3. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy.
Gong Y; Mu D; Prabhakar S; Moser A; Musolino P; Ren J; Breakefield XO; Maguire CA; Eichler FS
Mol Ther; 2015 May; 23(5):824-834. PubMed ID: 25592337
[TBL] [Abstract][Full Text] [Related]
4. Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency.
Dumser M; Bauer J; Lassmann H; Berger J; Forss-Petter S
Acta Neuropathol; 2007 Dec; 114(6):573-86. PubMed ID: 17828604
[TBL] [Abstract][Full Text] [Related]
5. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy.
Schlüter A; Espinosa L; Fourcade S; Galino J; López E; Ilieva E; Morató L; Asheuer M; Cook T; McLaren A; Reid J; Kelly F; Bates S; Aubourg P; Galea E; Pujol A
Hum Mol Genet; 2012 Mar; 21(5):1062-77. PubMed ID: 22095690
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
7. ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN.
O'Neill GN; Aoki M; Brown RH
Neurology; 2001 Dec; 57(11):1956-62. PubMed ID: 11739809
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy.
Monternier PA; Singh J; Parasar P; Theurey P; DeWitt S; Jacques V; Klett E; Kaur N; Nagaraja TN; Moller DE; Hallakou-Bozec S
J Inherit Metab Dis; 2022 Jul; 45(4):832-847. PubMed ID: 35510808
[TBL] [Abstract][Full Text] [Related]
9. Clinical, neuroimaging, biochemical, and genetic features in six Chinese patients with Adrenomyeloneuropathy.
Li J; Wang H; He Z; Wang X; Tang J; Huang D
BMC Neurol; 2019 Sep; 19(1):227. PubMed ID: 31526374
[TBL] [Abstract][Full Text] [Related]
10. Very-long-chain fatty acid metabolism in adrenoleukodystrophy protein-deficient mice.
Yamada T; Shinnoh N; Kondo A; Uchiyama A; Shimozawa N; Kira J; Kobayashi T
Cell Biochem Biophys; 2000; 32 Spring():239-46. PubMed ID: 11330052
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.
Moser AB; Liu Y; Shi X; Schrifl U; Hiebler S; Fatemi A; Braverman NE; Steinberg SJ; Watkins PA
J Cell Biochem; 2021 Oct; 122(10):1337-1349. PubMed ID: 34056752
[TBL] [Abstract][Full Text] [Related]
12. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
13. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
Singh J; Khan M; Singh I
Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
[TBL] [Abstract][Full Text] [Related]
14. Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Baarine M; Andréoletti P; Athias A; Nury T; Zarrouk A; Ragot K; Vejux A; Riedinger JM; Kattan Z; Bessede G; Trompier D; Savary S; Cherkaoui-Malki M; Lizard G
Neuroscience; 2012 Jun; 213():1-18. PubMed ID: 22521832
[TBL] [Abstract][Full Text] [Related]
15. Microglial dysfunction as a key pathological change in adrenomyeloneuropathy.
Gong Y; Sasidharan N; Laheji F; Frosch M; Musolino P; Tanzi R; Kim DY; Biffi A; El Khoury J; Eichler F
Ann Neurol; 2017 Nov; 82(5):813-827. PubMed ID: 29059709
[TBL] [Abstract][Full Text] [Related]
16. A novel ABCD1 gene mutation causes adrenomyeloneuropathy presenting with spastic paraplegia: A case report.
Liu J; Wang X; Huang D; Qi Y; Xu L; Shao Y
Medicine (Baltimore); 2024 Apr; 103(16):e37874. PubMed ID: 38640304
[TBL] [Abstract][Full Text] [Related]
17. Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2).
Genin EC; Geillon F; Gondcaille C; Athias A; Gambert P; Trompier D; Savary S
J Biol Chem; 2011 Mar; 286(10):8075-8084. PubMed ID: 21209459
[TBL] [Abstract][Full Text] [Related]
18. A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination.
Strachan LR; Stevenson TJ; Freshner B; Keefe MD; Miranda Bowles D; Bonkowsky JL
Hum Mol Genet; 2017 Sep; 26(18):3600-3614. PubMed ID: 28911205
[TBL] [Abstract][Full Text] [Related]
19. General aspects and neuropathology of X-linked adrenoleukodystrophy.
Ferrer I; Aubourg P; Pujol A
Brain Pathol; 2010 Jul; 20(4):817-30. PubMed ID: 20626743
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy.
Unterrainer G; Molzer B; Forss-Petter S; Berger J
Hum Mol Genet; 2000 Nov; 9(18):2609-16. PubMed ID: 11063720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
